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Being intolerant of tumors
 
sing the immune system to attack cancers is a good 
idea, but it may only work if Toll-like receptors 
(TLRs) are activated to break tolerance, say Yiping Yang 
(Duke University, Durham, NC), Drew Pardoll (Johns 
Hopkins, Baltimore, MD), and colleagues.
The favored method for delivering cancer immunotherapy 
has been dendritic cells: they are the central antigen-presenting 
cells for generating T cell responses; they can be grown in vitro 
in large quantities; and their use in mice with cancer led to some 
spectacular results. “That led to a whole wave of excitement,” 
says Pardoll. “But it hasn’t really panned out.”
Perhaps the biggest 
problem is tolerance. 
Most cancer immuno-
therapy focuses not on 
tumor-specific antigens, 
which vary too much 
because each tumor 
has different mutations, 
but on self-antigens 
that are overexpressed 
in the tumor. Although some collateral damage of normal 
self-tissue is alright for many tissues, the real problem is 
getting the immune response off the ground when it is 
challenged with a self-antigen.
Now Yang et al. show that viral but not dendritic cell 
vectors can do the job. Only the viral vectors can suppress 
tolerance to a cancer self-antigen in a mouse model, thus 
leading to increased survival. Ligands that activate TLRs 
also do the trick, and may be more promising in humans, 
as humans generally mount antibody responses that neutralize 
viral vectors.
 
 
 
 
 
Reference:
 
Yang, Y., et al. 2004. 
 
Nat. Immunol
 
. 10.1038/ni1059.
U
Toll ligands (black squares and 
triangles) augment antitumor 
vaccinations and increase survival.
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Telomeres 
together
 
n enzyme dissolves a 
unique pairing con-
nection between telo
 
-
 
meres, according to Jasmin 
Dynek and Susan Smith 
(New York University, 
New York, NY).
Overexpression of the 
enzyme, called tankyrase 1, 
is known to extend telo-
mere length—it makes 
TRF1 fall off telomeres so 
that telomerase can gain 
access. So presumably too 
A
Without tankyrase 1, centromeres 
(red) separate but telomeres (blue) 
stay together.
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little tankyrase 1 will have the opposite effect, and simply 
shorten telomeres.
Or not. Dynek and Smith now find that cells lacking 
tankyrase 1 have a completely unexpected phenotype. They 
arrest in mitosis when their telomeres, though not covalently linked, 
nevertheless fail to separate. Tankyrase 1 is a poly(ADP-ribose) 
polymerase that dissociates TRF1 from telomeres based on the 
excess negative charge of all those ADP-ribose groups on TRF1. 
Whether it is TRF1 or another protein that is the relevant target 
for dissolving telomere pairing is unknown.
Telomere pairing is known to help chromosomes pair during 
meiosis, and may help damaged telomeres to repair each other 
by homologous recombination. It appears that the tankyrase 
mechanism is used especially for regulating telomere pairing, 
either instead of or in addition to the separase–cohesin system 
used on chromosome arms. Smith is now interested in how this 
pairing is regulated during the cell cycle. 
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n active mechanism keeps vesicles 
that are departing the ER from 
turning round and fusing back to it, 
say Faustin Kamena and Anne Spang 
(Max Planck, Tübingen, Germany).
Directionality is a challenge for vesicle 
traffic. Although vesicles traveling 
from ER to Golgi and from Golgi to ER 
have very different job descriptions, 
recycling of transport proteins ensures 
that the compositions of the two vesicle 
types are similar if not identical. The 
two vesicle types start off with different 
coats (COPII for ER to Golgi and COPI 
for Golgi to ER) but shed them soon 
after departure.
A
 
Kamena and Spang figured that 
vesicles departing from the ER might 
be prevented from doing a U-turn by 
the same ER machinery that welcomes 
fusion of Golgi-derived vesicles. Sure 
enough, a mutant of the ER protein 
Tip20p allowed COPII vesicles, 
recently departed from the ER, to fuse 
back to the ER.
The researchers were lucky that they 
tested two different Tip20p mutants. 
Only one of those mutants (
 
tip20–8
 
, 
and not 
 
tip20–5
 
 or any of the other ER 
fusion mutants) showed the U-turn 
phenotype. Now, the team can look 
for suppressor mutations that rescue 
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tip20–8
 
 but not 
 
tip20–5
 
, and isolate 
proteins that bind only one of the two 
mutant proteins. Either approach may 
give clues about what, exactly, is 
sensed as different about a departing 
versus an arriving vesicle. 
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Only the tip20-8 mutant allows a protein 
to double-back to the ER for trimming. 
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